Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Heym

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Pediatric Blood & Cancer|April 15, 2026
Treatment of Vascular Anomalies With Sirolimus: Characterizing Practice Patterns of US Specialist CliniciansBryan A Sisk, Stephanie Milam, Christine Bereitschaft, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
JAMA Network Open|May 16, 2024
Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid LeukemiaJatinder K Lamba, Richard Marrero, Huiyun Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid LeukemiaRichard J Marrero, Huiyun Wu, Xueyuan Cao, et al.
Leukemia|May 4, 2021
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphomaStan Goldman, Matthew Barth, Bruce Shiramizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2019
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III TrialJeffrey E Rubnitz, Norman J Lacayo, Hiroto Inaba, et al.
Haematologica|January 22, 2026
Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium reportAshley N Chavana, Emily J Mason, John P Woodhouse, et al.
Pharmacotherapy|December 30, 2024
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemiaRachel D Harris, Olga A Taylor, M Monica Gramatges, et al.
The Oncologist|June 23, 2025
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemiaRachel D Harris, Olga A Taylor, Maria Monica Gramatges, et al.
American Journal of Hematology|February 18, 2022
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumLauren Pommert, Eric S Schafer, Jemily Malvar, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Pediatric Blood & Cancer|April 15, 2026
Treatment of Vascular Anomalies With Sirolimus: Characterizing Practice Patterns of US Specialist CliniciansBryan A Sisk, Stephanie Milam, Christine Bereitschaft, et al.
Journal for Immunotherapy of Cancer|March 22, 2019
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemiaRosa Nguyen, Huiyun Wu, Stanley Pounds, et al.
JAMA Network Open|May 16, 2024
Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid LeukemiaJatinder K Lamba, Richard Marrero, Huiyun Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2024
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid LeukemiaRichard J Marrero, Huiyun Wu, Xueyuan Cao, et al.
Leukemia|May 4, 2021
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphomaStan Goldman, Matthew Barth, Bruce Shiramizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2019
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III TrialJeffrey E Rubnitz, Norman J Lacayo, Hiroto Inaba, et al.
Haematologica|January 22, 2026
Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium reportAshley N Chavana, Emily J Mason, John P Woodhouse, et al.
Pharmacotherapy|December 30, 2024
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemiaRachel D Harris, Olga A Taylor, M Monica Gramatges, et al.
The Oncologist|June 23, 2025
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemiaRachel D Harris, Olga A Taylor, Maria Monica Gramatges, et al.
American Journal of Hematology|February 18, 2022
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumLauren Pommert, Eric S Schafer, Jemily Malvar, et al.
Pageof 3